Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Published:2022-11 Issue: Volume:173 Page:35-42
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ohuchi Mayu,Yagishita Shigehiro,Jo Hitomi,Akagi Kazumasa,Inaba Higashiyama Ryoko,Masuda Ken,Shinno Yuki,Okuma Yusuke,Yoshida Tatsuya,Goto Yasushi,Horinouchi Hidehito,Makino Yoshinori,Yamamoto Noboru,Ohe Yuichiro,Hamada Akinobu

Funder

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference24 articles.

1. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab;Lindauer;CPT Pharmacometrics Syst Pharmacol,2017

2. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors;Patnaik;Clin Cancer Res,2015

3. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer;Gandhi;N Engl J Med,2018

4. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer;Reck;N Engl J Med,2016

5. Dose escalation methods in phase I cancer clinical trials;Le Tourneau;J Natl Cancer Inst,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL;JTO Clinical and Research Reports;2024-07

2. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

3. Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?;British Journal of Cancer;2024-06-04

4. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia;Pharmacological Research;2024-01

5. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14